Objective To investigate the biocompatibility of type I collagen scaffold with rat bone marrow mesenchymal stem cell (BMSCs) and its role on proliferation and differentiation of BMSCs so as to explore the feasibility of collagen scaffold as neural tissue engineering scaffold. Methods Type I collagen was used fabricate collagen scaffold. BMSCs were isolated by density gradient centrifugation. The 5th passage cells were used to prepare the collagen scaffold-BMSCs complex. The morphology of collagen scaffold and BMSCs was observed by scanning electron microscope (SEM) and HE staining. The cell proliferation was measured by MTT assay at 1, 3, 5, and 7 days after culturein vitro. After cultured on collagen scaffold for 24 hours, the growth and adhesion of green fluorescent protein positive (GFP+) BMSCs were observed by confocal microscopy and live cell imaging. Results The confocal microscopy and live cell imaging results showed that GFP+ BMSCs uniformly distributed in the collagen scaffold; cells were fusiform shaped, and cell process or junctions between the cells formed in some cells, indicating good cell growth in the collagen scaffold. Collagen scoffold had porous fiber structure under SEM; BMSCs could adhered to the scaffold, with good cell morphology. The absorbance (A) value of BMSCs on collagen scaffold at 5 and 7 days after culture was significantly higher than that of purely-cultured BMSCs (t=4.472,P=0.011;t=4.819,P=0.009). HE staining showed that collagen scaffold presented a homogeneous, light-pink filament like structure under light microscope. BMSCs on the collagen scaffold distributed uniformly at 24 hours; cell displayed various forms, and some cells extended multiple processes at 7 days, showing neuron-like cell morphology. Conclusion Gelatinous collagen scaffold is easy to prepare and has superior biocompatibility. It is a promising scaffold for neural tissue engineering.
目的 探讨尤瑞克林对不同结构性影像类型进展性脑梗死的CT与临床效果。 方法 2007年3月－2011年6月按入院时不同结构性影像类型将进展性脑梗死分为大灶梗死、中灶梗死、小灶梗死及腔隙梗死4型，共235例，采用分层随机分组的方法将患者分为尤瑞克林组（治疗组）119例，对照组116例。两组基础用药均为疏血通6 mL+生理盐水250 mL静脉滴注，胞磷胆碱0.5 g+生理盐水250 mL静脉滴注，阿司匹林0.1 g口服，以上用药均为1次/d，连用4周。治疗组同时给予生理盐水100 mL+尤瑞克林0.15 PNAu静脉滴注，对照组同时给予生理盐水100 mL静脉滴注，1次/d，连用7～14 d，两组治疗前后均测量梗死的最大层面最大梗死灶的长度与宽度，计算并记录梗死面积；统计分析各型的临床疗效。 结果 ① 梗死面积改变：治疗前各亚型治疗组与对照组梗死面积差异均无统计学意义（P＞0.05）；治疗后，大灶梗死组、中灶梗死组、小灶梗死组中的治疗组梗死面积均比治疗前显著缩小（P＜0.01），而对照组的梗死面积较治疗前差异无统计学意义（P＞0.05）；腔隙梗死组中，治疗组及对照组治疗后梗死面积均无明显改变（P＞0.05）。② 临床疗效：各亚型进展性脑梗死，治疗组均取得优于对照组的效果；大灶梗死及中灶梗死的显著进步率分别为47.6%和66.7%，而对照组的显著进步率分别为0.0%和33.3%。 结论 大灶梗死组、中灶梗死组、小灶梗死组进展性脑梗死使用尤瑞克林治疗后梗死面积均比治疗前明显缩小；各亚型进展性脑梗死使用尤瑞克林后临床疗效均优于对照组，尤其是大灶梗死及中灶梗死的临床效果更加显著。